Long-term safety and efficacy of nevirapine-based HAART

Abstract number: P1194

Hidalgo C., Alvarez B., Bécares F., García Delgado R., Fernández Guerrero M., Górgolas M.

Objectives: To evaluate the safety and efficacy of long term NVP based HAART in HIV infected patients.

Methods: Retrospective study of 107 HIV infected patients who started NVP based HAART during 1998, 1999 or 2000, either as a first line therapy or as a simplification strategy.

Results: 107p with a mean age of 34.8 years, (81% men and 19% women), 82.2% and 18.8% acquired the infection by sexual and parenteral route respectively. The reasons to start NVP were: (a) simplification with undetectable viral load from PI based regimen 81p (75.7%), (b) previous PI failing regimen 13p (12.1%) and (c) naïve 13p (12.1%).

Overall, the mean time on NVP based HAART was 63m, median 48m (range 9–132m). 43p (40.1%) were still on NVP with undetectable viral load after 104 m (range 12–130m) of follow up. 64p (59.9%) discontinued NVP due to the following reasons: 1) Structured treatment discontinuation 27p (25%); 2) Virologic failure 14p (13%); 3) Toxicity 11p (10.2%); 4) Change in treatment strategy 6p (5.6%); 5) Other reasons 6p (5.6%). From baseline to end of follow up the mean increment of CD4 was 139±241 cells, the mean decrement in triglycerides was 48±178 mg/dL, and the mean total cholesterol did not change.

Conclusion: Nevirapine based HAART is a long term (more than 8 years) safe and effective therapy for HIV infected patients. Virologic failures ocurred in 13% of cases and drug related toxicity in 10.2%.

Session Details

Date: 10/04/2010
Time: 00:00-00:00
Session name: Abstracts 20th European Congress of Clinical Microbiology and Infectious Diseases
Location: Vienna, Austria, 10 - 13 April 2010
Presentation type:
Back to top